The bill adds a new Subpart to the Public Health Service Act creating the National Institute for Biomedical Research and Development (the Institute) inside the NIH. The Institute is empowered to perform “full‑cycle” drug, device, and biological product development — from clinical trials through commercialization — by using NIH labs, contracting, acquiring technologies and data, constructing facilities, and coordinating across federal agencies.
Crucially, the Institute must secure federal ownership of patents and related intellectual property for products developed or funded under its authority, publish research and clinical data, limit claims of trade secrets for funded projects, and either manufacture products publicly at cost or license them under public‑interest terms (defaulting to non‑exclusive, cost‑plus or free licenses to public/nonprofit entities and Medicines Patent Pool distribution). The bill also creates a 15‑member governing Board, requires health technology assessments to set value, mandates reporting and evaluation metrics, and authorizes $90 billion for fiscal year 2027 to stand up and operate the Institute.
At a Glance
What It Does
Creates the National Institute for Biomedical Research and Development within the NIH to carry out end‑to‑end development (including clinical trials), acquire rights to NIH‑supported inventions, own resulting patents and data, and make products available via public manufacturing or licensing under public‑interest terms. It requires formal health technology assessments and public disclosure of trial and cost data.
Who It Affects
Pharmaceutical and biotech companies that partner with or receive NIH funding; NIH institutes and laboratories; nonprofit and for‑profit manufacturers; public payers and health systems; patient groups and global health organizations that rely on lower‑cost access to medicines.
Why It Matters
The bill shifts the federal role from funder to developer and owner, overriding normal Bayh‑Dole practices for covered projects and setting new rules for IP, transparency, and pricing. That could lower prices and expand access for prioritized products but will also reshape technology transfer, contracting, and private investment incentives in biomedical research.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Medicines for the People Act creates a new institute inside the NIH charged with taking promising biomedical inventions through the full development lifecycle to regulatory approval and public availability. The Institute may do the work itself using NIH laboratories, build new facilities, run clinical trials, contract with external partners, acquire technologies and data, and coordinate across federal agencies to commercialize products addressing public health priorities.
The Board will set priorities based on potential public health impact and unmet needs; the Director executes the R&D program and carries out Board policies.
A central operational change is ownership and control of intellectual property: for inventions developed or funded under the Institute, the bill requires federal ownership of patents and related trade secrets and gives the Institute the right of first refusal on NIH‑supported inventions. The Institute must manage patents in the “public interest,” license patents freely to public and nonprofit entities, and make non‑exclusive, public‑interest licenses to for‑profit companies with protections such as cost‑plus pricing and reciprocity.
The bill also prescribes that, by default, patents be licensed to the Medicines Patent Pool unless the Director decides otherwise.Transparency is mandated across the board: safety and effectiveness data submitted to FDA, preclinical and clinical datasets, contract and licensing agreements, and summary findings must be published. Entities funded by the Institute must share scientific data in public repositories (preferably NIH‑affiliated), assign persistent identifiers, and place manuscripts in PubMed Central within a year of publication.
The bill bars claims of trade secret or confidential commercial information for products developed or funded under this authority, except as limited by the statutory definition of confidential commercial information.For manufacturing and access, the Director must provide for public manufacturing “if practicable” and sell such products at cost. If public manufacturing is impracticable, the Institute may license patents to private manufacturers, giving preference to nonprofits and reinvesting royalties into R&D.
Health technology assessments are required to inform value‑based licensing and pricing, and the bill builds in reporting and evaluation metrics (applications filed, patents filed/licensed/acquired, clinical datasets published, and estimated savings to public health programs). The statute authorizes $90 billion for FY2027 to launch the Institute and remains explicit about Secretary oversight and Board governance.
The Five Things You Need to Know
The bill authorizes $90,000,000,000 for fiscal year 2027 to establish and operate the Institute, funds to remain available until expended.
The Secretary must establish a 15‑member governing Board within 180 days, with no more than five members from the for‑profit sector and explicit prohibitions on recent lobbying or certain senior executive appointments.
For inventions resulting from NIH‑supported research, the Institute has a right of first refusal and, notwithstanding chapter 18 of title 35 (Bayh‑Dole), the Director must ensure federal ownership of patents and related trade secrets for products developed or funded under the Institute.
The bill requires broad public disclosure: all safety and effectiveness data submitted to FDA, clinical data sets, licensing agreements, and contracts must be published (entities funded by the Institute must deposit data in repositories and submit manuscripts to PubMed Central within one year).
Where the Institute holds patents, it must provide for public manufacturing and sale at cost when practicable; if licensing to private entities is necessary, patents are licensed free to public/nonprofit entities and to for‑profit companies under public‑interest terms (non‑exclusive, cost‑plus pricing, reinvestment of royalties).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Institute purpose, R&D program, and operations
This section establishes the Institute’s mission to run “full‑cycle” development of drugs, devices, and biologics aimed at public health priorities and to make resulting products available at equitable prices. It enumerates operational authorities: using NIH labs, contracting with external parties, acquiring technologies and data, building facilities, coordinating across agencies, and conducting clinical trials. Practically, the Director can both perform in‑house R&D and outsource or acquire projects — creating multiple pathways to move a discovery to market while keeping the Institute in the driver’s seat for federally prioritized products.
Health technology assessment, invention monitoring, and acquisition rules
The Institute must perform formal, multidisciplinary health technology assessments (HTAs) that consider clinical effectiveness, costs, ethical and social impacts, and downstream consequences; the HTA informs valuation and licensing decisions. The Director must monitor NIH and other public or private research for promising inventions and has a statutory right of first refusal to acquire rights to NIH‑supported inventions — a substantive change to how federally funded inventions move from labs to licensees.
IP, trade secrets, licensing, and manufacturing rules
The bill requires federal ownership of patents and related trade secrets for products developed or funded under the Institute and directs management of those rights in the public interest. Patents are to be licensed to the Medicines Patent Pool by default; public and nonprofit licenses must be free, and for‑profit licenses must include public‑interest protections (non‑exclusivity, cost‑plus pricing, reciprocity). The Director must either provide for public manufacturing and sale at cost or license manufacturing (with preference for nonprofit producers) while reinvesting royalties into further R&D.
Transparency and data sharing obligations
The Institute must publish preclinical and clinical data, all safety and effectiveness information submitted to FDA, contracts, and licenses. Funded entities must deposit scientific data to repositories (with persistent identifiers, access controls for sensitive data, and long‑term availability) and place manuscripts in PubMed Central within one year of publication. The statute expressly limits the Institute’s ability to claim trade secrets or confidential commercial information for covered projects, significantly narrowing grounds for withholding data.
Governing Board, oversight, reporting, and funding
The Secretary must appoint a 15‑member voting Board with specified civil society, patient advocate, public health, and Institute representation; membership limits and cooling‑off restrictions apply to industry lobbyists and certain corporate executives. The Secretary retains supervisory authority and may remove the Director. The Institute must evaluate and report annually (after an initial five‑year check) on metrics such as filings, patents, licenses, published datasets, and estimated public program savings. The bill also authorizes a one‑time $90 billion appropriation for FY2027 and makes conforming changes to the PHSA and criminal statutes to cover Board members under certain title 18 penalties.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Low‑income and medically underserved patients: The Institute’s public manufacturing at cost and public‑interest licensing terms aim to lower prices and increase supply for prioritized medicines domestically and in low‑ and middle‑income countries via the Medicines Patent Pool.
- Public payers and health systems (Medicare, Medicaid, VA): The bill builds mechanisms (cost‑priced supply and HTA‑informed licensing) that could reduce program drug expenditures and improve budget predictability; the Institute’s evaluations must estimate such savings.
- Global health organizations and LMICs: Default licensing to the Medicines Patent Pool and requirements to ensure access in low‑ and middle‑income markets create clearer pathways for generic production and broader global availability.
- NIH researchers and academic institutions: Stronger data‑sharing rules, repository requirements, and federal acquisition rights mean wider public access to datasets and potentially faster follow‑on research and collaboration.
- Nonprofit and public manufacturers: Preference in licensing and access to federally owned IP gives nonprofits and public manufacturers opportunities to produce drugs they otherwise could not access under private exclusive licenses.
Who Bears the Cost
- For‑profit pharmaceutical and biotech companies: The federal claim to patents and trade secrets, default MPP licensing, and constrained licensing terms reduce exclusivity rents and may lower future licensing income from NIH‑supported inventions.
- U.S. taxpayers (appropriations): The $90 billion FY2027 authorization funds the Institute’s launch and operations; taxpayers also absorb operational and capital costs if the Institute pursues public manufacturing.
- NIH institutes and intramural research programs: The Institute can draw on NIH personnel, facilities, and projects; this may divert resources, require reallocation of staff, or change NIH technology transfer workflows.
- Private contractors and licensees: Contracts with the Institute will likely include terms transferring IP and data to the federal government or imposing strict transparency and manufacturing obligations, altering commercial deal economics.
- Small biotech and startups that rely on NIH funding: Projects funded or acquired by the Institute may be subject to federal ownership rules, changing exit strategies and investor expectations for NIH‑supported companies.
Key Issues
The Core Tension
The central dilemma is straightforward: secure broad, public access to medically important products by vesting federal ownership, transparency, and production capacity in the government — or preserve private exclusivity and commercial incentives that many argue drive investment and scaling. The bill chooses public control to prioritize access, but in doing so risks reducing private incentives, creating legal conflict over invention rights, and confronting real-world constraints in manufacturing and valuation.
The bill creates a sharp legal and operational break with existing federal technology‑transfer norms. It asserts federal ownership of patents and trade secrets for Institute‑funded work “notwithstanding chapter 18 of title 35,” which calls into question how Bayh‑Dole principles will be reconciled in practice.
That phrasing invites legal challenges and will require careful rulemaking to determine when and how the Institute exercises its right of first refusal on NIH inventions, and what compensation (if any) flows to original inventors or contractors.
Transparency and the explicit bar on claiming trade secrets for covered products improve reproducibility and public access, but they also collide with longstanding FDA confidentiality pathways for manufacturing details, which are sometimes necessary to protect patient privacy or commercially sensitive information. Operationalizing public manufacturing is another practical hurdle: building or converting facilities, securing skilled staff, and establishing quality systems are capital‑ and time‑intensive.
If public manufacturing proves impracticable, licensing terms (cost‑plus, non‑exclusive) require robust HTA processes to set value; HTA methods and thresholds are politically and technically contested and will determine whether licenses deliver meaningful price reductions.
Finally, the bill trades increased public control for potential private‑sector disengagement. Pharmaceutical firms may alter collaboration strategies with NIH, shift R&D investment away from areas likely to be claimed by the Institute, or seek stronger contractual protections up front.
The Institute’s success depends on balancing public‑interest objectives with realistic incentives for private manufacturing partners and the need for clear, administrable IP and valuation rules.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.